- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Resting metabolic rate.
Displaying page 1 of 2.
EudraCT Number: 2017-000841-28 | Sponsor Protocol Number: DC2017DECREASE01 | Start Date*: 2017-08-14 |
Sponsor Name:VU University Medical Center | ||
Full Title: Combined effects of SGLT2 inhibition and GLP-1 receptor agonism on food intake, body weight and central satiety and reward circuits in obese T2DM patients | ||
Medical condition: Type 2 diabetes mellitus Obesity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006677-26 | Sponsor Protocol Number: 68797373 | Start Date*: 2022-06-22 | ||||||||||||||||
Sponsor Name:Maastricht University | ||||||||||||||||||
Full Title: Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease | ||||||||||||||||||
Medical condition: Healthy volunteers (non-alcoholic fatty liver disease) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004875-61 | Sponsor Protocol Number: 15778303 | Start Date*: 2016-02-05 |
Sponsor Name:CHU TOULOUSE | ||
Full Title: Influence of apelin on insulin sensitivity in type 2 diabetic volunteers | ||
Medical condition: type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005032-42 | Sponsor Protocol Number: 17-162 | Start Date*: 2020-04-20 |
Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | ||
Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease | ||
Medical condition: Diabetes Type 2 with existing cardiovascular disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-003557-21 | Sponsor Protocol Number: LixiBrain01 | Start Date*: 2019-02-06 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024585-22 | Sponsor Protocol Number: WILK3 | Start Date*: 2011-03-25 | |||||||||||
Sponsor Name:Imperial College Academic Healthsciences Centre | |||||||||||||
Full Title: What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? | |||||||||||||
Medical condition: Idiopathic or familial pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002309-36 | Sponsor Protocol Number: PDY15010 | Start Date*: 2018-02-21 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared ... | |||||||||||||
Medical condition: Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002568-27 | Sponsor Protocol Number: PM-C-0172 | Start Date*: 2006-05-08 | |||||||||||
Sponsor Name:Sanofi-Synthelabo Groupe | |||||||||||||
Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with... | |||||||||||||
Medical condition: Abdominally obese patients with metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000753-24 | Sponsor Protocol Number: DC2011LiBrain001 | Start Date*: 2011-10-13 | ||||||||||||||||
Sponsor Name:VU University Medical Center | ||||||||||||||||||
Full Title: Central effects of endogenous GLP-1 and the GLP-1 analog liraglutide on brain satiety and reward circuits and feeding behavior in diabetes. | ||||||||||||||||||
Medical condition: diabetes mellitus obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004085-15 | Sponsor Protocol Number: CF111/203 | Start Date*: 2011-11-04 | |||||||||||
Sponsor Name:Laboratories León Farma S.A | |||||||||||||
Full Title: Open-Label, Randomized Study to Evaluate the Influence on the Hormonal and Ovarian Activity of Two Different Dosages of Drospirenone (either 4.0 mg for 24 Days or 2.8 mg Daily for 28 Days) Over Two... | |||||||||||||
Medical condition: Evaluation of the influence of Drosperinone on the hormonal and ovarian activity, the bleeding pattern and the endometrial thickness. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004375-12 | Sponsor Protocol Number: TODINELI | Start Date*: 2014-02-13 | |||||||||||||||||||||
Sponsor Name:Center of Mech-Sense | |||||||||||||||||||||||
Full Title: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy | |||||||||||||||||||||||
Medical condition: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy i... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001634-26 | Sponsor Protocol Number: RPH001BEV01 | Start Date*: 2017-06-07 | |||||||||||
Sponsor Name:TRPHARM | |||||||||||||
Full Title: Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Pharmacokinetic and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Mal... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002080-88 | Sponsor Protocol Number: NA | Start Date*: 2005-09-13 | |||||||||||
Sponsor Name:Aintree Hospitals NHS Trust and University of Liverpool | |||||||||||||
Full Title: A double−blind, placebo−controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal | |||||||||||||
Medical condition: Obesity defined as BMI > 30 kg /m2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001513-33 | Sponsor Protocol Number: CF111/204 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: Phase II trial to evaluate the maintenance of ovulation inhibition with LF111 (drospirenone 4.0 mg 24/4 regimen) after scheduled 24-hour delays in pill intake. | |||||||||||||
Medical condition: Evaluation of ovulation inhibition with scheduled 24h delay in pill intake in healty young females of child bearing potential. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003426-24 | Sponsor Protocol Number: CTU079G | Start Date*: 2013-02-13 |
Sponsor Name:Riemser Pharma GmbH | ||
Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b... | ||
Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m² | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001959-11 | Sponsor Protocol Number: CL3-16257-056 | Start Date*: 2005-04-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales | |||||||||||||
Full Title: Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled int... | |||||||||||||
Medical condition: Coronary artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) FI (Completed) LV (Completed) IT (Completed) CZ (Completed) SK (Completed) GB (Completed) DK (Completed) AT (Completed) SE (Completed) EE (Completed) DE (Completed) IE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003332-23 | Sponsor Protocol Number: B1261007 | Start Date*: 2013-03-21 | |||||||||||
Sponsor Name:Pfizer Inc., 235 42nd Street, New York, NY 10017, USA | |||||||||||||
Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonis... | |||||||||||||
Medical condition: Diabetic nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) ES (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002127-28 | Sponsor Protocol Number: 16016762 | Start Date*: 2016-07-19 | |||||||||||
Sponsor Name:Hvidovre University Hospital | |||||||||||||
Full Title: The impact of subcutaneous glucagon before, during and after exercise. A study in patients with type 1 diabetes mellitus | |||||||||||||
Medical condition: Patients with type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000703-15 | Sponsor Protocol Number: A5351028 | Start Date*: 2007-06-19 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States | |||||||||||||
Full Title: A 15 MONTH, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF CP 945,598 IN PREVENTION OF WEIGHT REGAIN IN OBESE SUBJECTS | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001579-35 | Sponsor Protocol Number: KBP5074-2-001 | Start Date*: 2019-08-07 | ||||||||||||||||
Sponsor Name:KBP BioSciences Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disea... | ||||||||||||||||||
Medical condition: Moderate to Severe Chronic Kidney Disease and uncontrolled hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
